Pro 2014-020 (Framework Agreement on Jianfeng Group's Acquisition of Nestor)
Release time:
2020-08-05
Securities Code: 600668 Securities Short Name: Jianfeng Group Announcement No.: 2014-020
Bond Short Name: 13 Jianfeng 01 Bond Code: 122227
Zhejiang Jianfeng Group Co., Ltd.
Reminder Announcement on the Signing of Equity Transfer Framework Agreement by Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important Content Reminder:
l Transaction Brief Content: Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, recently signed the "Framework Agreement on Equity Transfer of Zhejiang Neshikang Pharmaceutical Co., Ltd." with Creative Medicine and Xi 'an Zizhitong Investment Co., Ltd. to transfer 70% and 25% of the equity of Zhejiang Neshikang Pharmaceutical Co., Ltd.
l This transaction does not constitute a related party transaction
l This transaction does not constitute a major asset reorganization
l There are no major legal obstacles to the implementation of the transaction
l This is a framework agreement, which is the preliminary result of the preliminary negotiations, and the follow-up work has been arranged. The specific matters of equity acquisition need to be further negotiated according to the results of audit, evaluation and due diligence. The formal equity transfer agreement will also be submitted to the company's board of directors or general meeting of shareholders for approval in accordance with the "Stock Listing Rules", the company's articles of association, etc., before it can take effect. There is uncertainty as to whether the equity acquisition will be realized.
Overview of 1. Transaction
Basic Information of (I) Transaction
Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), the controlling subsidiary of the Company, plans to acquire 70% equity of Zhejiang Neisikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Neisikang Pharmaceutical") held by Creative Medicine (hereinafter referred to as "CM Company") and Xi 'an Zizhitong Investment Co., Ltd. The company (hereinafter referred to as "Zizhitong Company") holds a 25% stake in Nesikang Pharmaceuticals, the total of the two is 95% equity.
(II) company approval.
This is a framework agreement. The specific matters of the equity acquisition need to be further negotiated and negotiated based on due diligence, audit or evaluation results, and will be in accordance with the provisions of the Stock Listing Rules, the company's articles of association, etc. It can be implemented after being submitted to the company's board of directors or shareholders meeting for approval. There is the possibility of changes in the implementation and implementation process of the framework agreement.
This equity transfer does not involve connected transactions, nor does it constitute a major asset reorganization as stipulated in the Measures for the Administration of Major Asset Reorganization of Listed Companies.
Basic Information of 2. Counterparty
(I) Creative Medicine
, Enterprise Name: Creative Medicine
2, Enterprise Nature: Limited Liability Company
3, Place of Registration: Cayman
, Main Office Location: 190 Elgin Street, Grand Cayman, Cayman Islands, ( KY1-9005)
, Legal Representative: Yang Zhi
, Paid-in Capital: US $13.5 million
7, Main Business: Investment and Investment Management
, Major Shareholder or Actual Controller: bioVeda China Fund II L.P.;New Enterprise Associates 13,Limited Partnership;Yifang Technology Group, Ltd.
9, 2013 main financial indicators: total assets of $41.0119 million, net assets of $13.3334 million, net profit of-$2800.
(II) Xi' an zizhitong investment co., ltd.
1, enterprise name: Xi' an zizhitong investment co., ltd.
2, enterprise nature: limited liability company (natural person investment or holding)
3, place of registration:
4 on the east side of the 10th floor of Zhongsheng Building, 69 Jinye Road, Xi 'an High-tech Zone, main office location:
5 on the east side of the 10th floor of Zhongsheng Building, 69 Jinye Road, Xi 'an High-tech Zone, legal representative: Zhang Hua
6, registered capital: 100 million yuan
7, main business: industrial investment and venture investment; asset management (excluding financial services), investment management and consulting.
8, major shareholder or actual controller: Zhang Hua
9, main financial indicators for 2013 (RMB): total assets of 257.0996 million yuan, net assets of 104.9223 million yuan, net profit of -5.3861 million yuan.
Basic Information of 3. Transaction Target
1, Target Name: 95 Equity of Zhejiang Nesikang Pharmaceutical Co., Ltd.;
2, major shareholder: CM Company holds 70% equity; Zizhitong Company holds 25% equity; zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. holds a 5% stake;
3, legal representative: Yang Zhi;
4, main business: drug bulk drug production; The main products are karat , azithromycin , fenofibrate, etc.
5, registered capital: US $36.10667 million;
6, Company Type: Limited Liability Company (Sino-foreign Joint Venture)
7, Establishment Date: December 23, 2002;
8, place of registration: 1318 Jinsha Street, Linjiang Industrial Zone, Wucheng District, Jinhua City;
9, Nesikang Pharmaceutical's 2013 financial report was audited by Jinhua Zhongjian Joint Accounting Firm, with main financial indicators:
Project (RMB 10,000) |
at the end of 2013 |
Total Assets |
43625.72 |
Total Liabilities |
26889.44 |
Net Assets |
16736.28 |
2013 |
|
Operating Income |
28776.51 |
Net Profit |
435.01 |
The company will entrust an audit institution with securities and futures business qualifications to carry out necessary audit on the financial statements of Neisikang Pharmaceutical, the audit results may differ from the above financial data. Main Contents of
4. Framework Agreement
"Party A": Zhejiang Jianfeng Pharmaceutical Co., Ltd.
"Party B": creative Medicine and Xi' an zizhitong investment co., ltd.
(I) equity transfer, price payment
1.CM company jointly transferred its 70% equity of nesikang pharmaceutical and zizhitong company its 25% equity of nesikang pharmaceutical to party a.
2, A and B agree on the transfer price after considering the audit, evaluation report, market trend and other comprehensive factors that may affect the operation efficiency.
3. The transfer price will be priced in RMB and paid to Party B in installments.
(II) Assets Evaluation
Within 15 working days after the signing of the framework agreement, intermediary agencies with securities qualification such as audit and evaluation hired by Party A and approved by Party B shall conduct a comprehensive audit, evaluation and due diligence on Neisikang Pharmaceutical, and strive to complete the audit, evaluation and due diligence within no more than 30 working days. Naisikang Pharmaceuticals and Party B shall provide the greatest convenience for the audit, evaluation and due diligence work, provide relevant information in a timely manner, and undertake to provide complete and true information required for the audit, evaluation and due diligence work. Otherwise, it will bear the corresponding legal responsibility.
(III) exclusive matters
Unless approved in writing by Party A, within 60 working days after this agreement comes into effect (hereinafter referred to as exclusive period), party B and any representative under its control shall not, directly or indirectly, seek to contact, negotiate, negotiate or sign any agreement or letter of intent with any third party (whether or not such agreement or letter of intent is binding on it) with respect to any matter agreed upon in this Agreement. During the exclusive period, Party B shall ensure the achievement of the transfer conditions, and the Buyer shall draft the equity transfer agreement and other transaction documents for negotiation. The term of this agreement and the exclusive period may be extended with the consent of the parties.
5. the impact and risk tips of this transaction
This equity acquisition is the specific implementation of the company's strategic plan and 2014 business plan. If the equity transfer can be successfully completed, it will expand the scope and scale of the company's pharmaceutical business.
In view of the fact that this framework agreement only determines the basic framework of the transaction, it is still necessary to further reach an equity transfer agreement on the basis of audit, evaluation and due diligence, and submit it to the company's board of directors or shareholders' meeting for consideration. There is uncertainty about whether the transaction can be realized. The company will be based on the progress of the acquisition of the progress of the timely disclosure of the follow-up progress, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
July 28, 2014
More information
Shanghai North Carolina passed the "Little Giant" annual acceptance
Recently, Shanghai Beika Pharmaceutical Technology Co., Ltd., a new member of Jianfeng Pharmaceutical Co., Ltd., successfully passed the annual acceptance of Shanghai science and technology "little giant" cultivation enterprise. In order to promote the independent innovation of enterprises, improve the core competitiveness of enterprises, enhance the competitive advantage of enterprises in domestic and foreign industries, and speed up the construction of scientific and technological innovation, Shanghai North Carolina applied for the Shanghai "Science and Technology Innovation Action Plan" science and technology "little giant" cultivation project in 2016 and was approved, becoming a member of 87 "little giant" cultivation enterprises in Shanghai in that year, with a project implementation period of 2 years. During the period of the Little Giant Cultivation Project, North Carolina completed the re-identification of Shanghai high-tech enterprises and the identification of Songjiang District Enterprise Technology Center. Songjiang District Enterprise Technology Center was evaluated as excellent, passed the certification of Shanghai Academician Expert Workstation, and passed the acceptance of Shanghai Patent Work Pilot Enterprises. A total of 4 invention patents were authorized, 12 invention patents were applied, 2 registered trademarks were applied, and 4 enterprise standards were formulated, there are 22 product testing reports. In 2017, Songjiang District's industry-university-research innovation project was approved and the project target was completed. Tinib drugs and their intermediates in non-small cell lung cancer (NSCLC) are the dominant varieties in North Carolina. In order to improve the existing tinib product line and consolidate the economic benefits and market share of this kind of products, North Carolina has not only conducted research and development on the latest generation of precision medical special-effect drugs such as cabozantinib (Cabozantinib) and ceritinib (Ceritinib), but also focused on the development of drug intermediates for tinib stars, which are hot spots in the pre-clinical research and development of generic drugs.
2020
07-31
The company held the 2017 Board of Directors and the Board of Supervisors
On April 20, Jiang Xiaomeng, chairman of the group company, presided over the 3rd meeting of the 10th board of directors of the company, and deliberated and passed 15 proposals and reports including the 2017 work report of the board of directors and the 2017 work report of the general manager. The general manager's report pointed out that in 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening standards, improving quality, improving management, and enhancing efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, and accelerating innovation Development, in-depth management integration, continuous improvement of management level, improvement of enterprise operation efficiency, strengthening of marketing expansion, and steady promotion of product sales growth, remarkable results have been achieved in technological innovation and technological transformation, the financial structure has been continuously improved, and the core competitiveness of enterprises has been further strengthened. The company achieved operating income of 2.827 billion yuan for the whole year, an increase of 18.81 percent over the same period last year, and realized net profit attributable to owners of the parent company of 348.4943 million yuan, an increase of 22.18 percent over the same period last year, another record high, with earnings per share of 1.01 yuan, achieving the best operating performance in the peak 60-year development process. Total assets at the end of the year were 4.176 billion yuan, an increase of 4.53 percent over the same period last year. In 2017, with the in-depth implementation of the national "One Belt One Road" initiative, cement off-peak production has been comprehensively promoted, industry environmental protection supervision has been further improved, energy conservation and consumption reduction supervision has become stricter, mergers and acquisitions have deepened, industry self-discipline awareness has continued to increase, and the cement industry supply-side structural reform has started.
2020
07-31
The peak represents the two sessions of Jinhua
From March 30 to April 3, March 31 to April 4, the second session of the seventh session of the Jinhua CPPCC and the third session of the seventh session of the Jinhua Municipal people's Congress were held successively. Three deputies to the National People's Congress and members of the CPPCC attended the meeting and actively offered suggestions and suggestions for the future development of Jinhua. Among the three performance suggestions put forward by Jiang Xiaomeng, chairman of the group company, two are about the real economy. He said that the development of the real economy in Jinhua City has encountered many bottlenecks in recent years. On the one hand, the operating costs of real enterprises have increased year by year and the profits have decreased, which has affected the development confidence and investment enthusiasm of entrepreneurs; on the other hand, the current new economic concepts are emerging one after another, and social capital is emerging. The loss of reality has caused a greater impact on the real economy. To this end, Jiang Xiaomeng suggested starting from five aspects to help Jinhua's real economy get rid of its predicament, that is, to create a good environment for investment and enterprises to enter households, such as competitive land elements, supporting public environmental protection facilities, and reasonable supporting industries. Development policies, abundant labor resources, etc.; the government conducts in-depth research on land, factories, taxes, subsidies, incentives, etc, further introduce various preferential policies and measures that are attractive and can stimulate the economic vitality of real enterprises; the combination of government investment promotion and "business investment promotion", and introduce corresponding guidance and incentive policies, through the introduction of business in gold enterprises, it is more convincing and easier to succeed; pay attention to helping existing local industrial enterprises and enhance their enthusiasm; vigorously promote outstanding business operators and entrepreneurs, and create a good atmosphere of respect for entrepreneurs, to boost the enthusiasm of the majority of entrepreneurs to invest in the construction of return home. About Small and Micro Enterprises
2020
07-31
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-31
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-30
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-31